Coccidioidomycosis is a fungal infection caused by Coccidioides species endemic to the desert south western United States. In healthy people, manifestations range mainly from asymptomatic to mild influenza-like syndrome. In immunosuppressed patients, extrapulmonary dissemination is common. We report the case of a patient with a parenchymal central nervous system lesion. This presentation is considered very rare. The highest risk of infection after solid organ transplantation occurs during the first year. Risk factors include treatment of acute rejection. In the reported case, the infection was probably donor-derived, as our patient had no history of traveling to endemic areas. Mortality is high among transplanted recipients with coccidioidomycosis, particularly those with disseminated infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1399-3062.2009.00456.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Coccidioidomycosis is endemic in the southwestern United States, Central America, and South America. Coccidioidomycosis has a variety of clinical presentations. Coccoidal meningitis is a feared form of disseminated coccidioidomycosis with high mortality and mobility rates.
View Article and Find Full Text PDFA Rare Complication of Proteus Brain Abscess Due to Coccidioidomycosis Causing Hydrocephalus.
J Investig Med High Impact Case Rep
August 2024
Kern Medical-UCLA, Bakersfield, USA.
is a very common gram-negative facultative anaerobe seen in urinary tract infections. This rod-shaped bacterium tends to cause urolithiasis via its ability to alkalinize the urine. However, in some cases, this bacterium has been shown to cause bacteremia as well as other complicated infections.
View Article and Find Full Text PDFEvaluation of nikkomycin Z with frequent oral administration in an experimental model of central nervous system coccidioidomycosis.
Microbiol Spectr
October 2024
Department of Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Article Synopsis
- The study investigated nikkomycin Z's effectiveness in treating central nervous system coccidioidomycosis in mice, showing significant improvements in survival and reduction of brain fungal burden compared to control.
- Mice were given nikkomycin Z at doses of 50, 100, and 300 mg/kg three times daily, or fluconazole, starting two days post-inoculation with the fungus.
- Nikkomycin Z targets fungal cell walls, making it a potentially safer treatment option than traditional antifungals, which can have adverse effects due to interactions with human enzymes.
Neurosarcoidosis, Coccidioidomycosis, or Both!
Int Med Case Rep J
December 2023
Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Article Synopsis
- A 57-year-old diabetic man initially diagnosed with coccidioidomycosis (CI) presented with vision problems in his left eye, leading to an MRI and other tests that showed signs of neurosarcoidosis instead.* -
- Despite starting antifungal therapy that provided minimal improvement, further biopsy and PET CT asserted the diagnosis of sarcoidosis, prompting a treatment shift to prednisone and later infliximab, effectively managing his symptoms.* -
- This case highlights the importance of accurate differential diagnosis, as symptoms of neurosarcoidosis can mimic those of other conditions like coccidioidomycosis, impacting treatment decisions.*
Innovative and potential treatments for fungal central nervous system infections.
Curr Opin Microbiol
December 2023
Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, FL, USA; Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA; Center for Immunology and Transplantation, Gainesville, FL, USA; Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA. Electronic address:
Fungal infections of the central nervous system (FI-CNS) are a problematic and important medical challenge considering that those most affected are immunocompromised. Individuals with systemic cryptococcosis (67-84%), candidiasis (3-64%), blastomycosis (40%), coccidioidomycosis (25%), histoplasmosis (5-20%), mucormycosis (12%), and aspergillosis (4-6%) are highly susceptible to develop CNS involvement, which often results in high mortality (15-100%) depending on the mycosis and the affected immunosuppressed population. Current antifungal drugs are limited, prone to resistance, present host toxicity, and show reduced brain penetration, making FI-CNS very difficult to treat.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!